Tribulus Terrestris for Erectile Dysfunction

Verdict: Tribulus is not a reliable ED treatment

The evidence that Tribulus terrestris treats erectile dysfunction is weak, inconsistent, and low-quality, and it should not be used in place of proven therapies such as PDE5 inhibitors. Major medical authorities do not endorse it for ED.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

The trial record is genuinely split, which is why this lands at the lowest evidence tier rather than a clean positive. A 2026 meta-analysis of 8 RCTs (PMID 40360723) did report a statistically significant gain on the IIEF-5 (MD 4.21), and the largest individual trial, Kamenov 2017 (n=180, double-blind; PMID 28364864), found a modest improvement of 2.70 IIEF points. But a 2025 systematic review (PMID 40219032) graded the overall evidence as low quality, with erectile function improving in only 3 of 5 studies and no reliable testosterone effect.

The positive signal does not hold up under scrutiny. A double-blind RCT (PMID 24630840) found Tribulus no better than placebo (p=0.79), and a 2018 multicenter trial (PMID 29901295) lacked any placebo arm, so its ~5.5-point gain cannot establish cause. Extract standardization varies between trials and the proposed testosterone mechanism is unconfirmed, leaving the effect biologically unexplained and unstable across studies.

Independent medical sources reinforce the cautious read. Mayo Clinic states that studies of natural ED supplements show 'they just don't work,' and Harvard Health and the EU's EFSA likewise do not back it; the US FDA flags sexual-enhancement supplements as a category prone to undeclared drug adulteration. The practical takeaway: any benefit is small and unreliable, and Tribulus is not a substitute for evidence-based ED treatment.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.39
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
81%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.15
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.385
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Tribulus terrestris for management of patients with erectile dysfunction: a systematic review and meta-analysis
PMID: 40360723 2026 統合分析 n = 8
Finding: TT significantly improved IIEF-5 (MD 4.21, p<0.00001) and IIEF-15 (MD 15.88, p=0.0004) vs placebo; no significant testosterone difference.
Effect size: MD 4.21 (IIEF-5); MD 15.88 (IIEF-15)
View on PubMed
Effects of Tribulus (Tribulus terrestris L.) Supplementation on Erectile Dysfunction and Testosterone Levels in Men—A Systematic Review
PMID: 40219032 2025 系統性回顧 n = 10
Finding: Low level of evidence; ED improved in only 3/5 studies; no robust evidence for testosterone increase; 8/10 studies showed no significant testosterone change.
View on PubMed
Evaluation of the efficacy and safety of Tribulus terrestris in male sexual dysfunction—A prospective, randomized, double-blind, placebo-controlled clinical trial
PMID: 28364864 2017 RCT (double-blind) n = 180
Finding: IIEF score significantly improved in TT vs placebo (p<0.0001); between-group difference 2.70 (95% CI 1.40–4.01); also improved intercourse satisfaction, orgasmic function, sexual desire.
Effect size: MD 2.70 IIEF points (95% CI 1.40–4.01)
View on PubMed
Results of a comparative multi-center randomized clinical study of efficacy and safety of EFFEX Tribulus and Tribestan in patients with erectile dysfunction
PMID: 29901295 2018 RCT (open-label) n = 173
Finding: Both TT preparations improved IIEF scores ~5.5 points; no placebo comparator limits causal inference.
🟠 Limited quality Effect size: ~5.5 IIEF points (within-group, no placebo control)
View on PubMed
Tribulus terrestris versus placebo in the treatment of erectile dysfunction: A prospective, randomized, double blind study
PMID: 24630840 2014 RCT (double-blind) n = 30
Finding: No between-group difference in IIEF-5 (p=0.7914); time factor significant within both groups (p=0.0004); TT not superior to placebo.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
須由中醫師處方使用(白蒺藜,衛署藥製字第011641號);未經確認其食用安全性前,不得供為食品原料使用。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Against
Studies looking to prove the efficacy of natural supplements show they just don't work source↗
L5d Harvard Health
Against
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-erectile-dysfunction-INT-tribulus-terrestris-001 繁體中文版 →